Background: Side effects of interferon-ribavirin combination therapy limit the sustained viral response achievable in a given HCV patient population. Furthermore, it has been suggested that higher ribavirin doses and longer treatment duration are required to achieve a sustained response rate in patients with genotype 1.
Coupling of ribavirin to hemoglobin offers the potential of a therapeutic with improved safety and efficacy by targeting the delivery of ribavirin to key tissues infected by viral infections such as HCV. These tissues include liver parenchymal cells and macrophages, both of which possess receptors for binding and internalization of hemoglobin-haptoglobin complexes as part of the natural clearance pathway for cell-free hemoglobin. Hemoglobin thus serves as a natural drug carrier for targeted therapy of such receptor-bearing tissues. Aim: To evaluate the effect of a ribavirinhemoglobin conjugate (RBV-Hb, HRC 203) in a mouse model of
